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Mitochondrial oxidative stress followed by membrane permeability transition (MPT) has been considered
as a possible mechanism for statins cytotoxicity. Statins use has been associated with reduced risk
of cancer incidence, especially prostate cancer. Here we investigated the pathways leading to
simvastatin-induced prostate cancer cell death as well as the mechanisms of cell death protection by
L-carnitine or piracetam. These compounds are known to prevent and/or protect against cell death
mediated by oxidative mitochondrial damage induced by a variety of conditions, either in vivo or in vitro.
The results provide evidence that simvastatin induced MPT and cell necrosis were sensitive to either L-
carnitine or piracetam in a dose-dependent fashion and mediated by additive mechanisms. When
combined, L-carnitine and piracetam acted at concentrations signiﬁcantly lower than they act individu-
ally. These results shed new light into both the cytotoxic mechanisms of statins and the mechanisms
underlying the protection against MPT and cell death by the compounds L-carnitine and piracetam.
& 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Statins are natural or synthetic compounds which inhibit the
conversion of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-
CoA) into mevalonic acid, the rate-limiting step in cholesterol
synthesis (Endo, 1992). These compounds are widely used in the
clinic for the treatment of hypercholesterolemia (Shepherd et al.,
1995; Collins et al., 2003) and many studies suggest an antiox-
idant effect of these compounds when used in therapeutic doses
(Cook et al., 1988; Guzman et al., 1993; Bhuiyan and Seccombe,
1996; Hsu et al., 2006). In addition, literature data indicate that
statins cause a series of adverse (Sirvent et al., 2005; Kwak et al.,
2012) or beneﬁcial (Manfredini et al., 2010; Li et al., 2010) effects
that include protection against prostate cancer (Oliveira et al.,
2008; Marcella et al., 2011; Mondul et al., 2011).
We have previously reported that, at 10 mM, simvastatin induced
mainly apoptosis in PC3 cells, which was prevented by mevalonic
acid but not by Cyclosporin A, an inhibitor of the mitochondrial
membrane permeability transition (MPT) (Oliveira et al., 2008). At
higher concentrations (60 mM), simvastatin induced necrosis, which
was prevented by Cyclosporin A but not by mevalonic acid. Cell
necrosis was preceded by a threefold increase in cytosolic free Ca2þ
and a signiﬁcant decrease in both respiratory rate and mitochondrial
membrane potential. Both mitochondrial dysfunction and necrosis: þ55 19 35217330.
.
ier OA license.were prevented by Cyclosporin A, indicating that necrosis, in this
model, is dependent on MPT (Oliveira et al., 2008).
MPT is a nonselective permeabilization of the inner mitochondrial
membrane, promoted by mitochondrial Ca2þ loading (Hunter et al.,
1976), changes in membrane structure (Ricchelli et al., 1999; Grijalba
et al., 1999) and oxidative stress (Vercesi, 1984; Fagian et al., 1990;
Kowaltowski et al., 2001; Figueira et al., in press). A recent study
(Vaseva et al., 2012) demonstrated that inhibition of MPT by
Cyclosporin A is mediated by the blockade of a p53-Cyclophilin D
(CypD) complex formation under oxidative stress-induced necrosis in
brain ischemia/reperfusion injury. The authors provided evidence that
p53 accumulates in the mitochondrial matrix in response to oxidative
stress and triggers permeability transition pore (PTP) opening and
necrosis by physical interaction with the PTP regulator CypD. This
study conﬁrms the participation of MPT in oxidative stress-induced
necrosis in cerebral stroke and other vascular disorders that are
leading causes of death (Vaseva et al., 2012). Therefore, targeting PTP
may provide avenues for therapeutic protection and/or prevention
against cell death that occurs in these pathologies.
A large body of evidences indicate that either L-carnitine or
piracetam prevent and/or ameliorate mitochondrial dysfunction
caused by a series of conditions either in vivo or in vitro (Moretti
et al., 2002; Virmani et al., 2005; Silva-Adaya et al., 2008; Elinos-
Calderon et al., 2009; Zhang et al., 2010). Therefore, the aims of
the present paper were two: ﬁrst, to dissect the events leading to
simvastatin induced MPT and cell death and second, to better
understanding the mechanisms underlie the protection by
L-carnitine and piracetam. The results indicate that L-carnitine
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induced superoxide generation thus protecting against MPT and
cell necrosis.2. Material and methods
2.1. Chemicals
Simvastatin (99.5% purity) was purchased from Galena Quı´mica
e Farmaceˆutica Ltda (Campinas, SP, Brazil). Piracetam was
obtained from BioLab Farmaceˆutica (S~ao Paulo, SP, Brazil). RPMI
1640 medium and fetal bovine serum (FBS) were obtained from
Cultilab (Campinas, SP, Brazil), L-carnitine, Cyclosporin A, carbonyl
cyanide p-triﬂuoromethoxyphenylhydrazone (CCCP), adenosine
5-diphosphate (ADP) dimethyl sulfoxide (DMSO), propidium iodide
and digitonin were obtained from Sigma (ST. Louis, MO, USA).
MitoSox was obtained from Life Technologies. All other chemicals
were standard commercial products of reagent-grade quality.2.2. Cell culture and simvastatin treatment
The PC3 human prostate cancer cell line was obtained from the
American Type Culture Collection (Rockville, MD, USA) and
maintained in RPMI 1640 medium supplemented with 10% FBS
and 10 mM (N-[2-hydroxyethyl]piperazine-N,-[2-ethanesulfonic
acid]; HEPES). The cells were maintained at 37 1C in air atmo-
sphere with 5% CO2. The cultures were maintained below 80%
conﬂuence. To evaluate the effects of simvastatin the cells were
plated in growth medium containing either 0.1% DMSO or
simvastatin dissolved in DMSO (stock solution of 100 mM) and
diluted in the culture medium immediately prior to use. When
indicated, cyclosporin A, L-carnitine and piracetam were also
added during the treatments.2.3. Flow cytometry analysis
Cell death was analyzed by ﬂow cytometry in a FACSCalibur
ﬂow cytometer (BD Biosciences, San Jose, CA, USA) equipped with
an argon laser and CellQuest software (version 4.1). Ten thousand
events were acquired for each sample. The PC3 population was
identiﬁed by their light-scattering characteristics, enclosed in
electronic gates, and analyzed for the intensity of the ﬂuorescent
probe signal, as described below.2.4. Analysis of cell viability by propidium iodide staining
PC3 were incubated with propidium iodide (PI, 1:50) imme-
diately before analyzing the samples in FACS. Necrosis was
quantiﬁed as the number of PI positive cells divided by the total
number of cells.2.5. Mitochondrial superoxide generation
For the quantiﬁcation of mitochondrial superoxide generation,
PC3 cells were treated with 6 mM L-carnitine, 6 mM piracetam or
4 mM L-carnitineþ4 mM piracetam in the presence or absence of
60 mM simvastatin for 2 h. Then they were harvested, washed
with cold PBS and trypsinized, followed by staining with 3 mM
MitoSox at 37 1C for 10 min. The samples were analyzed in the
FL-2 channel of the ﬂow cytometer (Payne et al., 2007).2.6. Determination of mitochondrial membrane potential (DCm) in
digitonin-permeabilized PC3 Cells
Mitochondrial membrane potential (DCm) in digitonin-
permeabilized cells was estimated as changes in the ﬂuorescence
of safranine O (Figueira et al., 2012), recorded using a spectro-
ﬂuorometer (Hitachi, model F4500, Tokyo, Japan), operating at
excitation and emission wavelengths of 495 and 586 nm, respec-
tively, with slit width of 5 nm. After treatment with simvastatin,
PC3 cells (106 cells) were permeabilized with 20 mM digitonin
(Campos et al., 2004) in 0.5 ml of standard reaction medium
(125 mM sucrose, 65 mM KCl, 10 mM Tris–HCl (pH 7.2), 2.5 mM
Na2HPO4, 0.33 mM EGTA, 5 mM succinate, and 5 mM safranine O)
under constant stirring at 37 1C, in a 0.5 ml thermostatically
sealed glass cuvette equipped with a magnetic stirrer.
2.7. Statistical analysis
The results from six independent experiments, except for
mitochondrial membrane potential (n¼4) and reactive oxygen
species (n¼3) measurements, are presented as means7SEM.
Comparisons between groups were performed using a one-way
Analysis of Variance (ANOVA) with Kruskal–Walliss post-hoc
analysis. The level of signiﬁcance was set at Po0.05.3. Results
3.1. Either L-carnitine or piracetam protect against PC3 cell death
induced by simvastatin
The effects of L-carnitine or piracetam on simvastatin-induced
cell death were investigated in PC3 cells treated during 2 h with
60 mM simvastatin (Oliveira et al., 2008). As analyzed by ﬂow
cytometry (Fig. 1 A and B), this treatment induced signiﬁcant
necrotic cell death. Either L-carnitine (A) or piracetam (B) caused a
dose-dependent protection; being 50% inhibition obtained at
concentrations in the range of 4 mM of either compound. An
almost complete protection was obtained at the concentration of
6 mM of either L-carnitine (A) or piracetam (B).
3.2. L-Carnitine or piracetam decreased the rate of mitochondrial
superoxide generation induced by simvastatin in PC3 cells
The effects of L-carnitine or piracetam on the rates of reactive
oxygen production by mitochondria were estimated by the
MitoSox method in PC3 cells treated or not with simvastatin for
2 h (Fig. 2). Simvastatin increased the rate of superoxide genera-
tion by 73% (black bar). Either L-carnitine or piracetan, at 6 mM,
signiﬁcantly decreased the rates of superoxide generation both in
the presence or absence of simvastatin. In the presence of
simvastatin the inhibition by 6 mM of either L-carnitine or
piracetan shifted the rates of superoxide production to the control
levels. In addition, Fig. 2 shows that the combination of
L-carnitine and piracetam, at the concentrations of 4 mM, also
shifted the rates of superoxide production to the levels induced
by the individual compounds, at the concentration of 6 mM.
3.3. Cyclosporin A, L-carnitine or piracetam protects PC3 cells
against MPT caused by simvastatin
Simvastatin-induced cell death had been associated with MPT
opening in PC3 cells (Oliveira et al., 2008). Thus, we investigated
whether L-carnitine or piracetam protect against DCm decrease
that occur prior to necrosis mediated by MPT. PC3 cells were
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Fig. 1. L-Carnitine or piracetam protect against PC3 cell necrosis induced by
simvastatin. PC3 cells were treated with 0.1% DMSO (control) or with
60 mM simvastatinþL-carnitine (A) or 60 mM simvastatinþpiracetam (B) for 2 h.
After treatment, cells were stained with propidium iodide to estimate dead cells.
Values represent the mean7SEM (n¼6). nPo0.05 control versus L-carnitine 0–
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Fig. 2. Protection by L-carnitine or piracetam against superoxide generation
induced by simvastatin in PC3 cells. Cells were treated with 6 mM L-carnitine or
6 mM piracetam or 4 mM L-carnitineþ4 mM piracetam in the presence (or absence)
of 60 mM simvastatin for 2 h. After this treatment they were stained with MitoSox
as described in Material and methods. Values represent the mean7SEM (n¼3).
nPo0.05 control versus L-carnitine 6 mM and Piracetam 6 mM, # Po0.05 control
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Fig. 3. Protective effects of Cyclosporin A, L-carnitine or piracetam on DCm
decrease of PC3 cells caused by simvastatin. PC3 cells (1106 cells) were treated
with 0.1% DMSO (control) or with 60 mM simvastatin in the presence (or absence)
of 0.5 mM Cyclosporin A, 4 mM L-carnitine, 4 mM piracetam or 4 mM
L-carnitineþ4 mM piracetam, as indicated in the ﬁgure. After these treatments
the cells were washed and resuspended in 0.5 ml of standard reaction medium
(125 mM sucrose, 65 mM KCl (pH 7.2), 2.5 mM Na2HPO4, 0.33 mM EGTA, 5 mM
safranine O and 5 mM succinate) for DCm measurements. The arrows indicate
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Fig. 4. Protection by the association of L-carnitine plus piracetam against PC3 cell
death. PC3 cells were treated with 4 mM L-carnitine, 4 mM piracetam or 4 mM L-
carnitineþ4 mM piracetam in the presence (or absence) of 60 mM simvastatin.
Values represent the mean 7SEM (n¼6). nPo0.05 control versus simvastatin
60 mM.
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cells were washed and placed in the standard reaction medium in
the presence of the ﬂuorescent dye safranine O. The permeabili-
zation of the plasma membrane by digitonin allows the entry of
safranine O in the cells, which binds to the inner mitochondrial
membrane in response to the proton gradient. This decreases theintensity of the ﬂuorescence emitted (Figueira et al., 2012). The
addition of CCCP leads to DCm elimination and release of
safranine O from the membrane, thus allowing for DCm estima-
tion. Simvastatin caused a large decrease in DCm sensitive to the
MPT inhibitor Cyclosporin A (Fig. 3, compare lines simvastatin and
simivastatinþCyclosporin A). Similar to the effects observed with
Cyclosporin A, the DCm decrease induced by simvastatin was
inhibited either by L-carnitine or piracetam alone, or additively by
the combination of these compounds (Fig. 3).
3.4. The combination of L-carnitine and piracetam has additive
effects on the protection against necrosis induced by simvastatin
The dose–response experiments shown in Fig. 1 indicated that,
at 4 mM, either L-carnitine or piracetam protected the PC3
cells against necrosis by 50%. In addition the experiments of
Fig. 3 indicated that the combination of these compounds have
additive effects on the protection against simvastatin induced
DCm decrease. In order to ascertain the different molecular
mechanisms of these compounds on the protection against cell
necrosis we used a combination of both, at the concentrations of
4 mM. Fig. 4 shows that the association of these compounds
increased their protective effects against cell necrosis from 50%
to about 100%.
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The results described above demonstrate that either L-carnitine
or piracetam protect against simvastatin-induced PC3 cell death
mediated by increased cytosolic Ca2þ concentrations. Considering
that calcium is a known signaling agent for mitochondrial reactive
oxygen generation, in the present study we investigated whether
preventing and/or ameliorating oxidative mitochondrial dysfunction
with L-carnitine (Binienda, 2003; Sener et al., 2004; Yapar et al.,
2007; Nishimura et al., 2008; Shen et al., 2008; Elinos-Calderon
et al., 2009; Ye et al., 2010; Ghavami et al., 2012) or protecting
against changes in mitochondrial membrane ﬂuidity by piracetam
(Keil et al., 2006) would prevent necrotic cell death induced by toxic
concentrations of simvastatin (Oliveira et al., 2008). The results
show that the necrotic death of PC3 cells was inhibited in a dose-
dependent manner by either L-carnitine or piracetam (Fig. 1). The
additive effects of these compounds conﬁrmed their concerted
actions through different mechanisms leading to the same ﬁnal
effect, that is, a decreased mitochondrial overproduction of the
superoxide anion induced by simvastatin (Fig. 2). Similar results
were also obtained with the primary ﬁbroblasts cell line GN16
obtained from normal gengival biopsy and the non-tumorigenic
immortalized cell line HaCaT, derived from human keratinocytes
(Costa, R.A.P., Fernandes, M.P. and Vercesi, A.E., unpublished results).
Literature data indicate that, at the concentrations used here,
statins promote cell death mediated by mitochondrial dysfunction
associated with alterations in calcium homeostasis (Sirvent et al.,
2005), inhibition of beta-oxidation (Kaufmann et al., 2006) and
partial inhibition of respiration (Kwak et al., 2012). Interestingly, all
these alterations stimulate reactive oxygen generation by mito-
chondria supporting the notion that oxidative stress is a common
denominator in statins toxicity. Therefore, we next discuss the
possible mechanisms underlying the protective effects of L-carni-
tine and piracetam on the simvastatin effects described above such
as cytosolic Ca2þ increase, MPT and reactive oxygen generation.
As it might occur in some degree in our experiments, L-carnitine
has been shown to stimulate beta-oxidation by increasing the
mRNA expression of carnitine palmitoyltransferase 1A. This pre-
vented free fatty acid induced oxidative stress and reduced
hepatotoxicity either in vitro or in vivo by enhancing mitochon-
drial function (Jun et al., 2011). Indeed, the property of free fatty
acids as mitochondrial oxidative damaging agents are very well
documented either in vivo (Madesh and Balasubramanian, 1997;
Ghosh et al., 2006; Tonin et al., 2010; Ruiz-Ramirez et al., 2011) or
in vitro (Yao et al., 2005; Zhou et al., 2009; Barazzoni et al., 2012).
With respect to the effect of statins on the mitochondrial electron
transport chain, current literature data indicate that like simvastatin
(Sirvent et al., 2005), the metabolic inhibitors 3-nitropropionic acid
(3-NTA) (Solesio et al., 2012), rotenone (Panov et al., 2005) and
1-methyl-4-phenylpyridinium (MPPþ) (Brill and Bennett, 2003)
inhibit electrons transport, at the levels of Complexes I or II
(Virmani et al., 2004, 2005; Binienda et al., 2005; Panov et al.,
2005; Vamos et al., 2010). This causes damage to Complex I and II,
presumably at the level of 4Fe–4S clusters (Panov et al., 2005). These
alterations diminish resistance to Ca2þ thus increasing probability
of MPT and necrotic cell death (Panov et al., 2005; Vaseva et al.,
2012). Since L-carnitine plays signiﬁcant neuroprotective effects
against all these conditions (Virmani et al., 2002, 2003) we propose
that L-carnitine, in addition to its metabolic role, may directly
interact with 4Fe–4S clusters decreasing the superoxide radical
generation. In this respect, it is worthy to mention that L-carnitine
has also the ability to bind Fe2þ (Gulcin, 2006) a transition metal,
supposed to participate in the mitochondrial oxidative stress that
leads to MPT (Castilho et al., 1995).
Concerning the molecular mechanisms of piracetam protec-
tion against simvastatin toxicity (Fig. 1B), we may consider thatpiracetam protects against changes in membrane ﬂuidity via
unspeciﬁc interactions with the polar head groups of the cellular
membranes (Keil et al., 2006). In this regard, we have previously
demonstrated that Ca2þ binding to inner membrane cardiolipins
causes alterations in membrane lipid organization that result in a
burst of mitochondrial superoxide generation that triggers MPT
(Grijalba et al., 1999). Therefore, it can be proposed that inhibition
of simvastatin-induced MPT and necrosis by piracetam is
mediated by membrane stabilization that minimizes Ca2þ stimu-
lated superoxide production (Fig. 2).
Having investigated PC3 toxicity of statins in vitro and the
protection by L-carnitine and piracetam, the question arises to
what extent our ﬁndings are relevant for the in vivo situation. The
plasma concentrations of statins after oral doses of 20–40 mg are
around 0.1 mmol/L (Kaufmann et al., 2006) much lower than the
toxic concentrations used in our assays. However, the lipophilic
nature of simvastatin, presumably, favors its accumulation into
the cells, as a function of time, rendering it difﬁcult to estimate its
effective concentrations in the mitochondrial environment.
Taken together, our investigations do not offer an explanation
for in vivo toxicity of simvastatin. Rather, the ﬁndings are more
relevant with respect to the understanding of MPT mechanisms
and the effects of L-carnitine, piracetam and their combination on
the protection against necrosis, either in tumor or non-tumorigenic
cells. According mounting evidences accumulated during recent
years (Lemasters et al., 2009; Rasola et al., 2010; Toman and
Fiskum, 2011; Figueira et al., in press; Kim et al., 2012) MPT-
induced necrosis underlies the pathogenesis of leading causes of
human death such as cerebral stroke and other vascular diseases
(Vaseva et al., 2012).Acknowledgments
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